US healthcare giant Johnson & Johnson (NYSE: JNJ) continued its M&A spending spree during May.
Merck & Co (NYSE: MRK), Biogen (Nasdaq: BIIB) and Merck KGaA (MRK: DE) were other pharma majors to spend big over the month. The tables and graphs below show the year's spending so far, comparing it to previous years, and offer a comparison of how much pharma's biggest companies are investing in M&A this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze